# Clinical efficacy and safety of tripterygium wilfordii glycosides in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis

## TL;DR

This study reviews the effectiveness and safety of Tripterygium wilfordii glycosides in treating idiopathic membranous nephropathy, finding some benefits but noting limitations in study quality.

## Contribution

A systematic review and meta-analysis evaluating TWG as a treatment for IMN, highlighting its potential and limitations.

## Key findings

- TWG improved total response rate and complete remission rate in IMN patients.
- TWG reduced 24-hour urinary protein and recurrence risk.
- High heterogeneity and risk of bias limit the conclusiveness of findings.

## Abstract

Idiopathic membranous nephropathy (IMN) is a common cause of nephrotic syndrome in adults, with current immunosuppressive therapies often limited by incomplete efficacy, significant toxicity, and high cost. Extracts from Tripterygium wilfordii, particularly its glycosides (TWG), have emerged as a potential alternative with immunomodulatory properties.

To evaluate the clinical efficacy and safety of TWG in the treatment of IMN.

We systematically searched PubMed, Embase, Cochrane Library, and Chinese databases from inception to September 2025. Randomized controlled trials (RCTs) and observational studies comparing TWG with standard therapies were included. Risk ratios (RR) and standardized mean differences (SMD) were pooled using a random-effects model.

This meta-analysis incorporated 20 studies (1,789 patients). TWG significantly improved the total response rate (RR = 1.27; 95% confidence interval (CI): 1.12–1.44), complete remission rate (RR = 1.81; 95% CI: 1.13–2.90), and reduced 24-h urinary protein (SMD = −2.09; 95% CI: 3.46 to −0.71) and recurrence risk (RR = 0.56; 95% CI: 0.37–0.86). However, the evidence was characterized by high heterogeneity (I2 > 50% for most efficacy outcomes) and a high risk of bias in 17 of the 20 included studies. No significant difference was observed in serum albumin (SMD = 1.20; 95% CI: 0.25–2.64) or the overall incidence of inadequately reported adverse events (RR = 0.93; 95% CI: 0.65–1.34).

TWG may represent a beneficial therapeutic strategy for IMN, potentially improving remission rates and reducing proteinuria. However, the conclusiveness of these findings is constrained by the high risk of bias in the primary studies, substantial heterogeneity, and inadequate safety reporting. Future robust, multi-regional RCTs are required to definitively establish its efficacy and safety profile.